OrphoMed: OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

(marketscreener.com) OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea in response to the COVID-19 pandemic. Frank J. Steinberg, D.O., Head of Medical Oversight and founding Chief Medical...https://www.marketscreener.com/news/OrphoMed-Pauses-Recruitment-for-Phase-2-Adaptive-Design-Study-of-ORP-101-for-Treatment-of-IBS-D--30282326/?utm_medium=RSS&utm_content=20200331